Table 1 Candidate markers of response* to Yondelis
From: Adding pharmacogenomics to the development of new marine-derived anticancer agents
Gene ID | Description |
|---|---|
IFITM2 | interfer on induced transmembrane protein 2 (1-8D) |
TP53 | tum or protein p53 (Li-Fraumeni syndrome) |
COL5A2 | collagen, type V, alpha 2 |
JUNB | jun B proto-oncogene |
BST2 | bone marrow stromal cell antigen 2 |
HHEX | hematopoietically expressed homeobox |
SERPINA3 | serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 |
ATF3 | activating transcription factor 3 |
ABL1 | v-abl Abelson murine leukemia viral oncogene homolog 1 |
BRCA1 | breast cancer 1, early onset |
ERCC2 XPD | excision repair cross-complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D) |
ERCC3 XPB | excision repair cross-complementing rodent repair deficiency, complementation group 3 (xeroderma pigmentosum group B complementing) |
PCNA | proliferating cell nuclear antigen |
POLD3 | polymerase (DNA directed), delta 3 (Interim) |
POLR2G | polymerase (RNA) II (DNA directed) polypeptide G |
PRKDC | protein kinase, DNA-activated, catalytic polypeptide |
PTTG1 | pituitary tumor-transforming 1 |
RAD17 | RAD17 homolog (S. pombe) |